Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2026
Lipocine reported a Q2 net loss of $2.6 million, or $0.32 per share, while cash reserves increased to $23.3 million from $14.9 million at year-end. The company disclosed that its Phase 3 trial of LPCN 1154 for postpartum depression did not meet its primary endpoint, citing data anomalies at a single site; it has scheduled an FDA guidance meeting and initiated a new trial.
Key figures
- Revenue
- 190099
- Revenue Yoy
- 54.7%
- Ga expenses
- 990956
- Rd expenses
- 2041389
- Cash position
- 23300000
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.